Cargando…

A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma

BACKGROUND: Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemotherapy. Because current treatments can cause severe long-term side effects and are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shanshan, Gong, Zhaojian, Oladimeji, Peter O., Currier, Duane G., Deng, Qipan, Liu, Ming, Chen, Taosheng, Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858705/ https://www.ncbi.nlm.nih.gov/pubmed/31788346 http://dx.doi.org/10.1186/s40164-019-0153-x

Ejemplares similares

High throughput screening identifies modulators of histone deacetylase inhibitors
por: Gaupel, Ann-Christin, et al.
Publicado: (2014)

Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma
por: Watanabe, Eri, et al.
Publicado: (2022)

High-throughput screening of histone deacetylases and determination of kinetic parameters using fluorogenic assays
por: Moreno-Yruela, Carlos, et al.
Publicado: (2021)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
por: Divsalar, Donya Naz, et al.
Publicado: (2020)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Sonic Hedgehog-Induced Histone Deacetylase Activation Is Required for Cerebellar Granule Precursor Hyperplasia in Medulloblastoma
por: Lee, Seung Joon, et al.
Publicado: (2013)

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
por: Phi, Ji Hoon, et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

HIGH THROUGHPUT YEAST REPLICATIVE LIFESPAN SCREEN UNCOVERS HISTONE DEACETYLASE HDA AS NOVEL REGULATOR OF AGING
por: Yu, Ruofan, et al.
Publicado: (2019)

Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes
por: Alshawli, Abdulelah S., et al.
Publicado: (2020)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Screening of selective histone deacetylase inhibitors by proteochemometric modeling
por: Wu, Dingfeng, et al.
Publicado: (2012)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
por: Badie, Amandine, et al.
Publicado: (2022)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells
por: ZHOU, WENJIE, et al.
Publicado: (2016)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jorge #, J., et al.
Publicado: (2022)

A protocol for high-throughput screening of histone lysine demethylase 4 inhibitors using TR-FRET assay
por: Wu, Qiong, et al.
Publicado: (2021)

Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors
por: Schweipert, Markus, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

An Unbiased Approach To Identify Endogenous Substrates of “Histone” Deacetylase 8
por: Olson, David E., et al.
Publicado: (2014)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Virtual screening and experimental validation of novel histone deacetylase inhibitors
por: Huang, Yan-xin, et al.
Publicado: (2016)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
por: Jiang, Li-Ping, et al.
Publicado: (2022)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
por: Sandonà, Martina, et al.
Publicado: (2023)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kbi896m2slaj6rm83c8ln19umg